PTPN11 and acute myeloid leukemia: In AML patients that progress or relapse after treatment with venetoclax and azacitidine, 27% of the patients had a N/KRAS mutation, and 22% a PTPN11 mutation [32,95], suggesting that these mutations are more frequently present in refractory or relapsed disease.